New drug combo aims to reduce surgeries for rare HPV throat condition
NCT ID NCT04645602
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This early-phase study tests two cancer drugs—lenvatinib (a daily pill) and pembrolizumab (an IV infusion)—in 20 adults with HPV-related recurrent respiratory papillomatosis (RRP) that has spread to the lungs. The goal is to see if the combination can shrink papillomas and reduce how often patients need surgery to clear their airways. The trial also monitors safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenvatinib (Lenvima) and pembrolizumab (Keytruda)
- What this could lead to
- If it works, this could point toward a drug treatment that reduces or eliminates the need for repeated surgeries to remove papillomas from the airways and lungs.
- What could go wrong
- This is a very early, small pilot study with only 20 people. The combination may cause significant side effects, and there is no guarantee it will shrink tumors or improve symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can the HPV vaccine fully protect transgender women and people with HIV?
- Tweets that tell a story: a new approach to boosting HPV vaccination
- Could HPV shots start earlier? study tests vaccine in kids as young as 4
- Massive rural health study aims to uncover heart and lung disease risks
- Immune cell therapy takes on HPV
- ERs may soon offer At-Home HPV tests to reach women who skip screenings